WILMINGTON, Del., July 23, 2026
Inhibikase Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy IKT-001 for the treatment of Pulmonary Arterial Hypertension (PAH). IKT-001, a prodrug of imatinib mesylate, is being developed as a once-daily oral therapy designed to target the abnormal vascular cell proliferation that drives PAH progression. The designation recognizes the significant unmet medical need associated with this rare and life-threatening disease, which affects approximately 50,000 people in the United States, while also providing important regulatory incentives that could support the therapy’s continued clinical development and future commercialization.
FDA Orphan Drug Designation Supports Rare Disease Development
The FDA Office of Orphan Products Development granted the designation based on the active moiety, imatinib, rather than the specific formulation of IKT-001. Orphan Drug Designation is awarded to investigational therapies intended to treat diseases affecting fewer than 200,000 patients in the United States and provides several development incentives. These include eligibility for tax credits on qualified clinical trial expenses, waivers of certain FDA user fees, and the potential for seven years of market exclusivity if the therapy receives regulatory approval. According to Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics, the designation marks another important milestone for the company and reflects the urgent need for innovative treatment options capable of addressing the progressive nature of PAH while improving patient outcomes.
Preclinical Data Highlights Potential Benefits of IKT-001
Inhibikase recently presented preclinical findings for IKT-001 at the American Thoracic Society International Conference, demonstrating encouraging improvements in pulmonary vascular remodeling and hemodynamic markers associated with PAH. The investigational therapy also showed the potential for lower gastrointestinal toxicity compared with conventional imatinib mesylate, an important consideration for long-term treatment. The company believes IKT-001 could become the first once-daily oral anti-proliferative therapy specifically developed for PAH, offering patients a more convenient treatment approach while targeting the underlying disease process rather than simply managing symptoms. These early findings support the continued advancement of IKT-001 through late-stage clinical development.
Advertisement
Global Phase 3 IMPROVE-PAH Trial Continues Enrollment
IKT-001 is currently being evaluated in the global Phase 3 IMPROVE-PAH clinical trial, a pivotal study enrolling patients across approximately 180 clinical sites worldwide. The trial is designed to assess the therapy’s ability to improve pulmonary vascular resistance and other clinically meaningful outcomes in patients living with Pulmonary Arterial Hypertension, a progressive disorder characterized by elevated pressure within the pulmonary arteries and abnormal remodeling of blood vessels in the lungs. Imatinib, the active compound underlying IKT-001, has more than 20 years of established clinical use in oncology and hematology, providing a well-characterized safety profile that supports its continued investigation in PAH. With FDA Orphan Drug Designation now secured and the Phase 3 program actively enrolling patients, Inhibikase continues to advance IKT-001 as a potential new therapeutic option for individuals affected by this serious rare cardiopulmonary disease.
Source: Inhibikase Therapeutics press release
